- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
AstraZeneca has stated that results from its Phase III trial of its COVID-19 vaccine AZD1222 showed 79% efficacy at preventing symptomatic COVID-19 and 100% at preventing severe disease, consistent across age and ethnicity and well tolerated. Vaccine efficacy was 80% for participants over the age of 65. The independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine as well as no increased risk of thrombosis among participants who received at least one dose of the vaccine.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
